

HR 853

Closing Loopholes for Orphan Drugs Act

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Feb 4, 2021

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Feb 5, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/853>

Sponsor

Name: Rep. Welch, Peter [D-VT-At Large]

Party: Democratic • **State:** VT • **Chamber:** Senate

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. McKinley, David B. [R-WV-1]	R · WV		Feb 4, 2021

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Feb 5, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Feb 4, 2021)

Closing Loopholes for Orphan Drugs Act

This bill revises the 340B Drug Pricing Program, which currently requires drug manufacturers to discount orphan drugs (i.e., drugs for rare conditions) for certain entities covered by the program. The bill discounts orphan drugs that are not being used to treat rare conditions for all entities covered by the program.

Actions Timeline

- **Feb 5, 2021:** Referred to the Subcommittee on Health.
- **Feb 4, 2021:** Introduced in House
- **Feb 4, 2021:** Referred to the House Committee on Energy and Commerce.